|
⚲
|
| Keyboard |
| Deerfield Management Company LP
✚
|
|
|---|---|
| CRD # | 157876 |
| SEC # | 801-73284 |
| CIK # | 0001009258 |
| AUM | 19.08 B (2026-03-26) |
| Employees | 189 (47% Investors, 0% Brokers) |
| Phone | 212-551-1600 |
| Address | 345 Park Avenue South New York, NY 10010 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Nuvalent Inc | 1.8 | ||
| UNUM Therapeutics Inc | 0.3 | ||
| Praxis Precision Medicines Inc | 0.3 | ||
| Upjohn Inc | 0.3 | ||
| United Therapeutics Corp | 0.3 | ||
| Revolution Medicines Inc | 0.2 | ||
| Celcuity Inc | 0.2 | ||
| Centene Corp | 0.2 | ||
| Zafgen Inc | 0.2 | ||
| Brookdale Senior Living Inc | 0.2 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Deerfield Healthcare Innovations Fund III-A LP | [2024-02-20] | 469.6 M | 169.6 M |
| Filed 2024-11-01 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Deerfield Healthcare Innovations Fund III LP | [2024-02-20] | 469.6 M | 414.7 M |
| Filed 2024-11-01 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | Deerfield Private Design Fund V LP | [2020-11-24] | 1,340.5 M | |
| Offered $2,500,000,000 · Filed 2020-07-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $2,500,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| HF | Deerfield Healthcare Innovations Fund II LP | [2019-08-29] | 774.9 M | |
| Offered $1,000,000,000 · Filed 2019-06-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,000,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| HF | Deerfield Private Design Fund IV LP | [2017-02-28] | 2,391.8 M | 3,851.0 M |
| Offered $2,500,000,000 · Filed 2016-11-25 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $300,000 · Remaining $108,250,000 · Duration One year or less · Revenue Not Applicable | ||||
| HF | Deerfield Healthcare Innovations Fund LP | [2015-10-28] | 550.0 M | 1,800.3 M |
| Offered $550,000,000 · Filed 2015-07-28 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $200,000 · Duration One year or less · Revenue Not Applicable | ||||
| HF | Deerfield Private Design Fund III LP | [2014-08-12] | 1,532.2 M | |
| Offered $1,600,000,000 · Filed 2014-04-02 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $1,600,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| HF | Deerfield International Master Fund LP | [2013-03-28] | 2,009.8 M | 1,284.9 M |
| Filed 2017-03-02 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $250,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Deerfield PDI Financing II LP | 2013-03-28 | 35.3 M | |
| HF | Deerfield Private Design International II LP | [2013-03-28] | 270.6 M | 80.3 M |
| Filed 2010-12-17 (D) · Exemption 506, 3(c), 3(c)(7) · Minimum $125,000 · Remaining Indefinite · Duration One year or less · Net Assets $25,000,001 - $50,000,000 | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 12 | 19.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 12 | 19.1 |
| By Discretionary | ||
| Discretionary | 12 | 19.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 12 | 19.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.1 | |
| United States Persons | 19.0 | |
| Total | 12 | 19.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Peter Young | Director | 116 | 22 | |
| Graham Cook | Director | 79 | 20 | |
| Nicholas Lane | Director | 13 | 5 | |
| James Flynn | Director, Executive Officer | 21 | 2 | |
| Deerfield Mgmt Hif III LP | Promoter | 2 | 1 | |
| Je Flynn Capital Hif III LLC | Promoter | 2 | 1 | |
| J E Flynn Capital III LLC | Executive Officer | 1 | 1 | |
| Deerfield Mgmt III LP | Executive Officer | 1 | 1 | |
| Deerfield Mgmt IV LP | Executive Officer | 1 | 1 | |
| Je Flynn Capital IV LLC | Executive Officer | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001009258] | |
| 3 | [0001009258] | |
| 4 | [0001009258] | |
| SC 13D | [0001009258] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Deerfield Management Company LP Series C | DA32 Life Science Tech Acquisition Corp | [2021-08-10] |
| Deerfield Management Company LP Series C | Deerfield Healthcare Technology Acquisitions Corp | [2020-07-30] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $4.3B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 5493009YAY9MTF1EQS20 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Zafgen Inc LRMR
Common Stock
|
2026-02-27 | Buy | 1,084,012 | $5.00 | 5,420,060 |
|
Zafgen Inc LRMR
Common Stock
|
2026-02-27 | Buy | 831,978 | $5.00 | 4,159,890 |
|
Zafgen Inc LRMR
Common Stock
|
2026-02-27 | Buy | 2,000,000 | $5.00 | 10,000,000 |
|
Zafgen Inc LRMR
Common Stock
|
2026-02-27 | Buy | 1,084,010 | $5.00 | 5,420,050 |
|
Nuvalent Inc NUVL
Class A Common Stock
|
2025-11-24 | Sell | 371,287 | $95.45 | 35,439,344 |
|
Nuvalent Inc NUVL
Class A Common Stock
|
2025-11-24 | Sell | 371,287 | $95.45 | 35,439,344 |
|
Zafgen Inc LRMR
Common Stock
|
2025-07-31 | Buy | 3,387,539 | $3.20 | 10,840,125 |
|
Zafgen Inc LRMR
Common Stock
|
2025-07-31 | Buy | 2,599,932 | $3.20 | 8,319,782 |
|
Zafgen Inc LRMR
Common Stock
|
2025-07-31 | Buy | 3,387,529 | $3.20 | 10,840,093 |
|
ARS Pharmaceuticals Inc SPRY
Class A Common Stock
|
2025-06-27 | Sell | 370,074 | $18.46 | 6,831,566 |
|
ARS Pharmaceuticals Inc SPRY
Class A Common Stock
|
2025-06-27 | Sell | 370,075 | $18.46 | 6,831,584 |
|
Nuvalent Inc NUVL
Stock Option (Right to Buy) · derivative
|
2025-06-18 | Grant | 4,147 | $0.00 | |
|
Nuvalent Inc NUVL
Class A Common Stock
|
2025-06-18 | Grant | 2,647 | $0.00 | |
|
Nuvalent Inc NUVL
Class A Common Stock
|
2025-06-18 | Grant | 2,647 | $0.00 | |
|
Nuvalent Inc NUVL
Stock Option (Right to Buy) · derivative
|
2025-06-18 | Grant | 4,147 | $0.00 | |
|
Zafgen Inc LRMR
Stock Option (Right to Buy) · derivative
|
2025-05-13 | Grant | 19,000 | $0.00 | |
|
BiomX Inc PHGE
Warrants · derivative
|
2025-04-21 | Grant | 1,611,864 | ||
|
BiomX Inc PHGE
Warrants · derivative
|
2025-04-21 | Grant | 1,611,864 | ||
|
BiomX Inc PHGE
Stock Option (Right to Buy) · derivative
|
2025-04-14 | Grant | 17,600 | $0.00 | |
|
BiomX Inc PHGE
Warrants · derivative
|
2025-02-27 | Grant | 1,258,614 | ||
| showing 20 of 200 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Hildene Capital Management LLC
✚
|
CT | 20.18 B |
|
Blackstone Liquid Credit Strategies LLC
✚
|
NY | 18.79 B |
|
Altimeter Capital Management LP
✚
|
CA | 18.75 B |
|
Fundsmith LLP
✚
|
18.51 B | |
|
Rock Creek Group LLC
✚
|
DC | 18.38 B |
|
Saba Capital Management LP
✚
|
NY | 18.30 B |
|
Greenoaks Capital Partners LLC
✚
|
CA | 18.27 B |
|
BlackRock Alternatives Management LLC
✚
|
NY | 18.00 B |
|
Boothbay Fund Management LLC
✚
|
NY | 17.99 B |
|
Omers Infrastructure US Limited
✚
|
NY | 17.83 B |